Corporate Logo(source: samsungbiologics.com)
Samsung Biologics (207940) continued its upward momentum for a sixth consecutive session on October 15, buoyed by strong earnings expectations.
As of 9:18 a.m., the company’s shares were trading at 1,097,000 won, up 70,000 won (6.82%) from the previous day on the Korea Exchange.
Analysts attributed the sustained rally to growing anticipation of robust third-quarter results. Kiwoom Securities projected that Samsung Biologics would post consolidated revenue of 1.62 trillion won, up 37 percent from a year earlier, and an operating profit of 646.2 billion won, up 91 percent year-on-year.
Heo Hye-min, an analyst at Kiwoom Securities, said, “Revenue and operating profit are expected to exceed market consensus estimates of 1.55 trillion won and 505.2 billion won by about 5 percent and 28 percent, respectively.” She added, “A favorable exchange rate, milestone payments from Samsung Bioepis, and operating leverage from full utilization of Plant 4 are expected to drive strong earnings performance.”
[KOSPI] Samsung Biologics(207940), an affiliate of the Samsung Group, is ranked No. 1 in the global CMO market, producing cutting-edge biopharmaceuticals for domestic and foreign pharmaceutical companies. The market capitalization is 72.897 trillion won (as of October 14, 2025, closing price).
Corporate Logo(source: samsungbiologics.com)
Samsung Biologics (207940) continued its upward momentum for a sixth consecutive session on October 15, buoyed by strong earnings expectations.
As of 9:18 a.m., the company’s shares were trading at 1,097,000 won, up 70,000 won (6.82%) from the previous day on the Korea Exchange.
Analysts attributed the sustained rally to growing anticipation of robust third-quarter results. Kiwoom Securities projected that Samsung Biologics would post consolidated revenue of 1.62 trillion won, up 37 percent from a year earlier, and an operating profit of 646.2 billion won, up 91 percent year-on-year.
Heo Hye-min, an analyst at Kiwoom Securities, said, “Revenue and operating profit are expected to exceed market consensus estimates of 1.55 trillion won and 505.2 billion won by about 5 percent and 28 percent, respectively.” She added, “A favorable exchange rate, milestone payments from Samsung Bioepis, and operating leverage from full utilization of Plant 4 are expected to drive strong earnings performance.”
[KOSPI] Samsung Biologics(207940), an affiliate of the Samsung Group, is ranked No. 1 in the global CMO market, producing cutting-edge biopharmaceuticals for domestic and foreign pharmaceutical companies. The market capitalization is 72.897 trillion won (as of October 14, 2025, closing price).